Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial
Yelena Y. Janjigian(Memorial Sloan Kettering Cancer Center), Akihito Kawazoe(National Cancer Center Hospital East), Yuxian Bai(Harbin Medical University), Jianming Xu(Chinese PLA General Hospital), Sara Lonardi(Istituto Oncologico Veneto), Jean Phillipe Metges(Centre Hospitalier Régional Universitaire de Brest), Patricio Yañez(Universidad de La Frontera), Lucjan Wyrwicz(The Maria Sklodowska-Curie National Research Institute of Oncology), Lin Shen(Peking University), Yuriy Ostapenko(National Cancer Institute), Mehmet Bilici(Atatürk University), Hyun Cheol Chung(Yonsei University), Kohei Shitara(National Cancer Center Hospital East), Shukui Qin(China Pharmaceutical University), Eric Van Cutsem(Universitair Ziekenhuis Leuven), Josep Tabernero, Kan Li(Merck & Co., Inc., Rahway, NJ, USA (United States)), Chie‐Schin Shih(Merck & Co., Inc., Rahway, NJ, USA (United States)), Pooja Bhagia(Merck & Co., Inc., Rahway, NJ, USA (United States)), Sun Young Rha(Yonsei University)
Cited by 453
Abstract
Related Papers
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Martin M. Oken, Richard H. Creech, Douglass C. Tormey et al.|American Journal of Clinical Oncology|1982|11.6k